TechnoStart

TechnoStart is a venture capital organisation with over € 80 million under management. Since 1991, we have focused on Seed & Early Stage Technology companies in the fields of Applied Physics, Life Sciences, Chemistry and New Materials. TechnoStart has the experience and expertise to assist entrepreneurs in establishing companies from scratch. They believe in the enormous scientific and technological potential at European academic institutes waiting to be turned into business. This is why they have developed their Technology Radar designed to generate their own dealflow through the pro-active monitoring of selected scientific fields and institutes.

Karl Heinz

Principal Shareholder and Managing Director

5 past transactions

VISME

Grant in 2016
VISME rehabilitation service. Medical service providing new opportunities for rehabilitation. They work at the junction of neurobiology and machine learning. They use computer vision technologies to automatize the methods of rehabilitation.

Novaled

Series C in 2009
Novaled AG is a world-class technology provider in organic light-emitting diode (OLED) technologies. With expertise in synthetic and analytical chemistry, it offers complete solutions for the organic electronic markets, commercializing Novaled's Doping technology and materials. Novaled has developed long-term partnerships with major OLED players worldwide. Its strong IP position in OLED technology is based on more than 500 patents granted or pending. In operation since March 2003, Novaled is headquartered in Dresden, Germany with branch offices in Asia.

Ascendis Pharma

Series A in 2007
Ascendis Pharma has built a high value pipeline with the aim of changing clinical treatment paradigms. Using our innovative TransCon prodrug technology platform, we continue to identify new opportunities addressing areas of high unmet medical need. TransCon is applicable to all drug classes, and is currently being used to create superior prodrugs of proteins, peptides and small molecules. Depending on choice of TransCon Carrier, either systemic or localized drug exposure is achieved, while dosing frequency is determined by the choice of TransCon Linker. The prodrugs are new chemical entities with new patent life. Product development process is de-risked, as the prodrugs release the active component in its native and unmodified form, maintaining the original drug’s well known mode of action.

Novaled

Series B in 2005
Novaled AG is a world-class technology provider in organic light-emitting diode (OLED) technologies. With expertise in synthetic and analytical chemistry, it offers complete solutions for the organic electronic markets, commercializing Novaled's Doping technology and materials. Novaled has developed long-term partnerships with major OLED players worldwide. Its strong IP position in OLED technology is based on more than 500 patents granted or pending. In operation since March 2003, Novaled is headquartered in Dresden, Germany with branch offices in Asia.

NXN Software

Series C in 2001
NXN Software is supplier of Digital Asset and Production Management solutions for the computer graphics and digital entertainment industries.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.